Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (4 quarters reported)
$38.6M in Q4 2023 → $19M now. Hover for any quarter.
As reported for the quarter ended September 30, 2024. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Lyell Immunopharma Inc | 53.6% | Trimmed 3.8% | 7,390,710 | $10.2M |
| Adagene Inc | 46.4% | Unchanged | 3,982,902 | $8.84M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 3 quarters.
quarter ended September 30, 2024 · filed November 08, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lyell Immunopharma Inc | Trimmed | −291,446 | −$402K | 53.6% |
quarter ended June 30, 2024 · filed August 06, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Lyell Immunopharma Inc | Trimmed | −498,522 | −$723K | 47.7% |
quarter ended March 31, 2024 · filed May 07, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| AB Ambrx Biopharma Inc | Exited | −1,000,000 | −$14.2M | — |
| Adagene Inc | Trimmed | −242,794 | −$680K | 37.9% |
| Purple Biotech Ltd | Exited | −194,139 | −$151K | — |
| Castle Biosciences Inc | Exited | −6,636 | −$143K | — |
Loading...
